1
|
Borkar RM, Gajji S, Mohammed SA, Srivastava M, Reddy VG, Jala A, Asthana S, Kamal A, Banerjee SK, Ragampeta S. Identification and characterization of in vitro and in vivo fidarestat metabolites: Toxicity and efficacy evaluation of metabolites. J Mass Spectrom 2021; 56:e4694. [PMID: 33410180 DOI: 10.1002/jms.4694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 11/30/2020] [Accepted: 12/03/2020] [Indexed: 06/12/2023]
Abstract
The progression of diabetic complications can be prevented by inhibition of aldose reductase and fidarestat considered to be highly potent. To date, metabolites of the fidarestat, toxicity, and efficacy are unknown. Therefore, the present study on characterization of hitherto unknown in vitro and in vivo metabolites of fidarestat using liquid chromatography-electrospray ionization tandem mass spectrometry (LC/ESI/MS/MS) is undertaken. In vitro and in vivo metabolites of fidarestat have been identified and characterized by using LC/ESI/MS/MS and accurate mass measurements. To identify in vivo metabolites, plasma, urine, and feces samples were collected after oral administration of fidarestat to Sprague-Dawley rats, whereas for in vitro metabolites, fidarestat was incubated in human S9 fraction, human liver microsomes, and rat liver microsomes. Furthermore, in silico toxicity and efficacy of the identified metabolites were evaluated. Eighteen metabolites have been identified. The main in vitro phase I metabolites of fidarestat are oxidative deamination, oxidative deamination and hydroxylation, reductive defluroniation, and trihydroxylation. Phase II metabolites are methylation, acetylation, glycosylation, cysteamination, and glucuronidation. Docking studies suggest that oxidative deaminated metabolite has better docking energy and conformation that keeps consensus with fidarestat whereas the rest of the metabolites do not give satisfactory results. Aldose reductase activity has been determined for oxidative deaminated metabolite (F-1), and it shows an IC50 value of 0.44 μM. The major metabolite, oxidative deaminated, did not show any cytotoxicity in H9C2, HEK, HEPG2, and Panc1 cell lines. However, in silico toxicity, the predication result showed toxicity in skin irritation and ocular irritancy SEV/MOD versus MLD/NON (v5.1) model for fidarestat and its all metabolites. In drug discovery and development research, it is distinctly the case that the potential for pharmacologically active metabolites must be considered. Thus, the active metabolites of fidarestat may have an advantage as drug candidates as many drugs were initially observed as metabolites.
Collapse
Affiliation(s)
- Roshan M Borkar
- Analytical Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Changsari, 781101, India
| | - Shankar Gajji
- Analytical Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India
| | - Soheb A Mohammed
- Non-Communicable Diseases Group, Translational Health Science and Technology Institute (THSTI), Faridabad, 121001, India
| | - Mithul Srivastava
- Non-Communicable Diseases Group, Translational Health Science and Technology Institute (THSTI), Faridabad, 121001, India
| | - Velma Ganga Reddy
- Department of Organic Synthesis & Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India
| | - Aishwarya Jala
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Changsari, 781101, India
| | - Shailendra Asthana
- Non-Communicable Diseases Group, Translational Health Science and Technology Institute (THSTI), Faridabad, 121001, India
| | - Ahmed Kamal
- Department of Organic Synthesis & Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India
| | - Sanjay K Banerjee
- Non-Communicable Diseases Group, Translational Health Science and Technology Institute (THSTI), Faridabad, 121001, India
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Changsari, 781101, India
| | - Srinivas Ragampeta
- Analytical Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India
| |
Collapse
|
2
|
Burmistrov V, Morisseau C, D'yachenko V, Karlov D, Butov GM, Hammock BD. Imidazolidine-2,4,5- and pirimidine-2,4,6-triones - New primary pharmacophore for soluble epoxide hydrolase inhibitors with enhanced water solubility. Bioorg Med Chem Lett 2020; 30:126908. [PMID: 31870649 PMCID: PMC6957307 DOI: 10.1016/j.bmcl.2019.126908] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Revised: 12/09/2019] [Accepted: 12/10/2019] [Indexed: 11/28/2022]
Abstract
A series of inhibitors of the soluble epoxide hydrolase (sEH) containing imidazolidine-2,4,5-trione or pirimidine-2,4,6-trione has been synthesized. Inhibition potency of the described compounds ranges from 8.4 μM to 0.4 nM. The tested compounds possess higher water solubility than their preceding ureas. Molecular docking indicates new bond between the triones and the active site of sEH that in part explain the observed potency of the new pharmacophores. While less potent than the corresponding ureas, the modifications of urea group reported herein yield compounds with higher water solubility, thus permitting easier formulation.
Collapse
Affiliation(s)
- Vladimir Burmistrov
- Department of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, CA 95616, USA; Department of Chemistry, Technology and Equipment of Chemical Industry, Volzhsky Polytechnic Institute (Branch) Volgograd State Technical University, Volzhsky 404121, Russia
| | - Christophe Morisseau
- Department of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, CA 95616, USA
| | - Vladimir D'yachenko
- Department of Chemistry, Technology and Equipment of Chemical Industry, Volzhsky Polytechnic Institute (Branch) Volgograd State Technical University, Volzhsky 404121, Russia
| | - Dmitry Karlov
- Skolkovo Institute of Science and Technology, Skolkovo Innovation Center, Moscow 143026, Russia; Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia; Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Moscow Region 142432, Russia
| | - Gennady M Butov
- Department of Chemistry, Technology and Equipment of Chemical Industry, Volzhsky Polytechnic Institute (Branch) Volgograd State Technical University, Volzhsky 404121, Russia
| | - Bruce D Hammock
- Department of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, CA 95616, USA.
| |
Collapse
|
3
|
Gorshkov K, Wang AQ, Sun W, Fisher E, Frigeni M, Singleton M, Thorne N, Class B, Huang W, Longo N, Do MT, Ottinger EA, Xu X, Zheng W. Phosphocyclocreatine is the dominant form of cyclocreatine in control and creatine transporter deficiency patient fibroblasts. Pharmacol Res Perspect 2019; 7:e00525. [PMID: 31859463 PMCID: PMC6924099 DOI: 10.1002/prp2.525] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 08/20/2019] [Accepted: 08/29/2019] [Indexed: 12/26/2022] Open
Abstract
Creatine transporter deficiency (CTD) is a metabolic disorder resulting in cognitive, motor, and behavioral deficits. Cyclocreatine (cCr), a creatine analog, has been explored as a therapeutic strategy for the treatment of CTD. We developed a rapid, selective, and accurate HILIC ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method to simultaneously quantify the intracellular concentrations of cCr, creatine (Cr), creatine-d3 (Cr-d3), phosphocyclocreatine (pcCr), and phosphocreatine (pCr). Using HILIC-UPLC-MS/MS, we measured cCr and Cr-d3 uptake and their conversion to the phosphorylated forms in primary human control and CTD fibroblasts. Altogether, the data demonstrate that cCr enters cells and its dominant intracellular form is pcCr in both control and CTD patient cells. Therefore, cCr may replace creatine as a therapeutic strategy for the treatment of CTD.
Collapse
Affiliation(s)
- Kirill Gorshkov
- National Center for Advancing Translational SciencesNational Institutes of HealthBethesdaMDUSA
| | - Amy Q. Wang
- National Center for Advancing Translational SciencesNational Institutes of HealthBethesdaMDUSA
| | - Wei Sun
- National Center for Advancing Translational SciencesNational Institutes of HealthBethesdaMDUSA
| | - Ethan Fisher
- National Center for Advancing Translational SciencesNational Institutes of HealthBethesdaMDUSA
| | - Marta Frigeni
- Division of Medical GeneticsDepartment of PediatricsUniversity of UtahSalt Lake CityUTUSA
| | - Marc Singleton
- National Center for Advancing Translational SciencesNational Institutes of HealthBethesdaMDUSA
| | - Natasha Thorne
- National Center for Advancing Translational SciencesNational Institutes of HealthBethesdaMDUSA
| | - Bradley Class
- National Center for Advancing Translational SciencesNational Institutes of HealthBethesdaMDUSA
| | - Wenwei Huang
- National Center for Advancing Translational SciencesNational Institutes of HealthBethesdaMDUSA
| | - Nicola Longo
- Division of Medical GeneticsDepartment of PediatricsUniversity of UtahSalt Lake CityUTUSA
- Associated Regional and University Pathologists (ARUP) LaboratoriesSalt Lake CityUTUSA
| | | | - Elizabeth A. Ottinger
- National Center for Advancing Translational SciencesNational Institutes of HealthBethesdaMDUSA
| | - Xin Xu
- National Center for Advancing Translational SciencesNational Institutes of HealthBethesdaMDUSA
| | - Wei Zheng
- National Center for Advancing Translational SciencesNational Institutes of HealthBethesdaMDUSA
| |
Collapse
|
4
|
Merali Z, Ross S, Paré G. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. ACTA ACUST UNITED AC 2015; 29:143-51. [PMID: 24988246 DOI: 10.1515/dmdi-2014-0009] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2014] [Accepted: 05/16/2014] [Indexed: 11/15/2022]
Abstract
Human carboxylesterase 1 (CES1) and carboxylesterase 2 (CES2) are serine esterases responsible for the hydrolysis of ester and amide bonds present in a number of pharmaceutical products. Several common genetic variants of the CES1 and CES2 genes have been shown to influence drug metabolism and clinical outcomes. Polymorphisms of the CES1 gene have been reported to affect the metabolism of dabigatran etexilate, methylphenidate, oseltamivir, imidapril, and clopidogrel, whereas variants of the CES2 gene have been found to affect aspirin and irinotecan. Although the findings of these studies may be preliminary, they demonstrate the potential clinical utility of CES polymorphisms; however, more research is required, especially with respect to CES2. In this review, we outline the functional, molecular, and genetic properties of CES1 and CES2, and highlight recent studies that have shown relations between CES1 and CES2 variants and contemporary pharmacotherapy.
Collapse
|
5
|
Kurosawa Y, DeGrauw TJ, Lindquist DM, Blanco VM, Pyne-Geithman GJ, Daikoku T, Chambers JB, Benoit SC, Clark JF. Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency. J Clin Invest 2012; 122:2837-46. [PMID: 22751104 PMCID: PMC3408730 DOI: 10.1172/jci59373] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2012] [Accepted: 05/23/2012] [Indexed: 01/06/2023] Open
Abstract
The second-largest cause of X-linked mental retardation is a deficiency in creatine transporter (CRT; encoded by SLC6A8), which leads to speech and language disorders with severe cognitive impairment. This syndrome, caused by the absence of creatine in the brain, is currently untreatable because CRT is required for creatine entry into brain cells. Here, we developed a brain-specific Slc6a8 knockout mouse (Slc6a8-/y) as an animal model of human CRT deficiency in order to explore potential therapies for this syndrome. The phenotype of the Slc6a8-/y mouse was comparable to that of human patients. We successfully treated the Slc6a8-/y mice with the creatine analog cyclocreatine. Brain cyclocreatine and cyclocreatine phosphate were detected after 9 weeks of cyclocreatine treatment in Slc6a8-/y mice, in contrast to the same mice treated with creatine or placebo. Cyclocreatine-treated Slc6a8-/y mice also exhibited a profound improvement in cognitive abilities, as seen with novel object recognition as well as spatial learning and memory tests. Thus, cyclocreatine appears promising as a potential therapy for CRT deficiency.
Collapse
Affiliation(s)
- Yuko Kurosawa
- Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Neurology and
Department of Radiology and Imaging Research Center, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Emergency Medicine and
Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Reproductive Science, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Psychiatry and Behavior Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA
| | - Ton J. DeGrauw
- Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Neurology and
Department of Radiology and Imaging Research Center, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Emergency Medicine and
Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Reproductive Science, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Psychiatry and Behavior Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA
| | - Diana M. Lindquist
- Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Neurology and
Department of Radiology and Imaging Research Center, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Emergency Medicine and
Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Reproductive Science, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Psychiatry and Behavior Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA
| | - Victor M. Blanco
- Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Neurology and
Department of Radiology and Imaging Research Center, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Emergency Medicine and
Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Reproductive Science, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Psychiatry and Behavior Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA
| | - Gail J. Pyne-Geithman
- Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Neurology and
Department of Radiology and Imaging Research Center, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Emergency Medicine and
Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Reproductive Science, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Psychiatry and Behavior Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA
| | - Takiko Daikoku
- Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Neurology and
Department of Radiology and Imaging Research Center, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Emergency Medicine and
Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Reproductive Science, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Psychiatry and Behavior Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA
| | - James B. Chambers
- Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Neurology and
Department of Radiology and Imaging Research Center, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Emergency Medicine and
Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Reproductive Science, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Psychiatry and Behavior Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA
| | - Stephen C. Benoit
- Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Neurology and
Department of Radiology and Imaging Research Center, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Emergency Medicine and
Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Reproductive Science, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Psychiatry and Behavior Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA
| | - Joseph F. Clark
- Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Neurology and
Department of Radiology and Imaging Research Center, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Emergency Medicine and
Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Reproductive Science, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Psychiatry and Behavior Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA
| |
Collapse
|
6
|
Vale N, Fernandes I, Moreira R, Mateus N, Gomes P. Comparative analysis of in vitro rat liver metabolism of the antimalarial primaquine and a derived imidazoquine. Drug Metab Lett 2012; 6:15-25. [PMID: 22372552 DOI: 10.2174/187231212800229273] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2011] [Revised: 01/19/2012] [Accepted: 01/20/2012] [Indexed: 05/31/2023]
Abstract
The present study provides proof-of-concept regarding the expectedly high enzymatic stability of primaquinederived imidazolidin-4-ones, imidazoquines, formerly developed as alternatives to the parent antimalarial with potentially improved oral bioavailability [J. Med. Chem., 2009, 52, 7800-7807]. This study provides relevant experimental evidence on the remarkably low propensity of imidazoquines to undergo metabolic conversions mediated by rat liver enzymes. This, together with favourable key ADME parameters previously predicted for these compounds [Bioorg. Med. Chem. Lett. 2009, 19, 6914-6917], and proven lack of acute toxicity in mice, further reinforces the role of imidazoquines as reference leads for the development of novel primaquine surrogates. This is a particularly relevant issue in the present status of malaria chemotherapy worldwide, where primaquine remains the sole drug in clinical use able to block transmission between infected persons and the insect vector and to effectively act on liver-stage parasite forms, including hypnozoites.
Collapse
Affiliation(s)
- Nuno Vale
- Centro de Investigacao em Quimica da Universidade do Porto, Departamento de Quimica e Bioquimica, Faculdade de Ciencias, Universidade do Porto, Rua do Campo Alegre, 687, 4169-007 Porto, Portugal
| | | | | | | | | |
Collapse
|
7
|
Saczewski J, Hudson AL, Rybczyńska A. 2-[(Arylmethoxy)imino]imidazolidines with potential biological activities. Acta Pol Pharm 2009; 66:671-680. [PMID: 20050531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A series of 2-[(arylmethoxy)imino]imidazolidines was synthesized by reacting 2-chloro-4,5-dihydroimidazole with corresponding O-arylmethylhydroxylamines and evaluated for their alpha-, alpha2-adrenergic and imidazoline I1, I2 receptor binding affinities. The most potent 2-[(naphthalen-1-ylmethoxy)imino]imidazolidine showed a high selectivity and good affinity for the [3H]prazosin-labeled alpha1-adrenoceptors (K(i) = 107 nM). Representative compounds of this series were also tested in vivo for possible circulatory effects in rats after intravenous administration.
Collapse
Affiliation(s)
- Jarosław Saczewski
- Department of Chemical Technology of Drugs, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland.
| | | | | |
Collapse
|
8
|
Yamamoto D, Takai S, Jin D, Inagaki S, Tanaka K, Miyazaki M. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol 2007; 43:670-6. [PMID: 17884087 DOI: 10.1016/j.yjmcc.2007.08.002] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2007] [Revised: 07/10/2007] [Accepted: 08/03/2007] [Indexed: 11/18/2022]
Abstract
To investigate the inhibitory specificity of angiotensin converting enzyme (ACE) inhibitors to matrix metalloproteinase (MMP)-9, we predicted molecular interactions between an ACE inhibitor imidapril and MMP-9 active site based on recent X-ray structural analyses. Two binding modes differing in the orientation of imidapril on the active site were identified, and its hydrophobic group appeared to preferentially interact with the S1 site compared with the S1' site. Compared with the lisinopril-MMP-9 model in our previous study, imidapril was stabilized effectively on the active site with less of molecular distortions. We also measured ACE and MMP-9 inhibitory activities of imidapril and lisinopril after myocardial infarction. Imidapril had a stronger inhibitory activity against MMP-9 than lisinopril. These findings show that imidapril inhibits MMP-9 directly like lisinopril and its hydrophobic interactions with the S1 site of MMP-9 would be important for enhancing inhibitory activity.
Collapse
Affiliation(s)
- Daisuke Yamamoto
- Biomedical Computation Center, Osaka Medical College, 2-7 Daigakuchou, Takatsuki, Osaka 569-8686, Japan.
| | | | | | | | | | | |
Collapse
|
9
|
Lo ACY, Cheung AKH, Hung VKL, Yeung CM, He QY, Chiu JF, Chung SSM, Chung SK. Deletion of aldose reductase leads to protection against cerebral ischemic injury. J Cereb Blood Flow Metab 2007; 27:1496-509. [PMID: 17293845 DOI: 10.1038/sj.jcbfm.9600452] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Previously, we reported that transgenic mice overexpressing endothelin-1 in astrocytes showed more severe neurological deficits and increased infarct after transient focal ischemia. In those studies, we also observed increased level of aldose reductase (AR), the first and rate-limiting enzyme of the polyol pathway, which has been implicated in osmotic and oxidative stress. To further understand the involvement of the polyol pathway, the mice with deletion of enzymes in the polyol pathway, AR, and sorbitol dehydrogenase (SD), which is the second enzyme in this pathway, were challenged with similar cerebral ischemic injury. Deletion of AR-protected animals from severe neurological deficits and large infarct, whereas similar protection was not observed in mice with SD deficiency. Most interestingly, AR(-/-) brains showed lowered expression of transferrin and transferrin receptor with less iron deposition and nitrotyrosine accumulation. The protection against oxidative stress in AR(-/-) brain was also associated with less poly(adenosine diphosphate-ribose) polymerase (PARP) and caspase-3 activation. Pharmacological inhibition of AR by Fidarestat also protected animals against cerebral ischemic injury. These findings are the first to show that AR contributes to iron- and transferrin-related oxidative stress associated with cerebral ischemic injury, suggesting that inhibition of AR but not SD may have therapeutic potential against cerebral ischemic injury.
Collapse
Affiliation(s)
- Amy C Y Lo
- Department of Anatomy, The University of Hong Kong, Hong Kong SAR, China
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Caviness GO, Labadia ME, Giblin PA, Woska JR, Last-Barney K, Jeanfavre DD, Morelock MM. The determination and correlation of molecular and cellular equilibrium Kd and kinetic koff values for small molecule allosteric antagonists of LFA-1. Biochem Pharmacol 2007; 74:98-106. [PMID: 17482579 DOI: 10.1016/j.bcp.2007.03.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2006] [Revised: 02/20/2007] [Accepted: 03/08/2007] [Indexed: 11/22/2022]
Abstract
Molecular K(d) and k(off) parameters are often used to define the molecular potency of drugs. These constants, however, are determined on purified target proteins, and their relationship to in vivo binding phenomena is poorly understood. Herein, we report two novel assays to determine the off-rates of allosteric antagonists from lymphocyte function-associated antigen 1 (LFA-1). The SPR assay involves using the non-blocking mAb TS2/4 to immobilize full-length LFA-1 on a hydrophilic chip surface, and the soluble, native ligand sICAM-1 to probe the fraction of free LFA-1. To determine the fraction of free LFA-1 on cell surfaces, a flow cytometry assay was developed utilizing the fluorophore-labeled Fab R3.1. The R3.1 antibody has been previously demonstrated to block the ability of both ICAM-1 and antagonists to bind to purified and cell-surface LFA-1. The molecular and ex vivo cellular parameters were determined for a set of nine structurally-related LFA-1 allosteric antagonists. The relationships between the parameters determined in the ELISA (K(d)), SPR (k(off)), and flow cytometry (k(off)) assays were shown to be linear with slopes approximately equal to 1, and a correlation analysis showed that the three assay datasets were equivalent at the alpha=0.05 level. These results were unexpected, as the ELISA and SPR assays involve high affinity LFA-1, and the flow cytometry assays involve cell surface LFA-1 in whole-blood, in which a distribution of affinity states would be expected. Nevertheless, the results presented herein show that the K(d) and k(off)'s determined in molecular assays can be used as predictors of LFA-1 receptor occupancy in ex vivo assays.
Collapse
Affiliation(s)
- Gary O Caviness
- Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877-0368, USA
| | | | | | | | | | | | | |
Collapse
|
11
|
Poria RB, Norenberg JP, Anderson TL, Erion J, Wagner CR, Arterburn JB, Larson RS. Characterization of a radiolabeled small molecule targeting leukocyte function-associated antigen-1 expression in lymphoma and leukemia. Cancer Biother Radiopharm 2007; 21:418-26. [PMID: 17105416 DOI: 10.1089/cbr.2006.21.418] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVE Leukocyte function-associated antigen-1 (LFA-1) is constitutively expressed on leukocytes, including overexpression on lymphomas and leukemias. We have developed a derivative of BIRT 377, an allosteric inhibitor of LFA-1, which may be chemically tagged without affecting binding. In this study, we modified this derivative, (R)-1-(4-aminobutyl)-5-(4-bromobenzyl)-3-(3,5-dichlorophenyl)-5-methylimidazolidine- 2,4-dione (butylamino-NorBIRT), and demonstrated its potential as a noninvasive imaging agent. METHODS Specific binding of fluorescein-labeled butylamino-NorBIRT to both human and murine cells was demonstrated using equilibrium binding and dissociation techniques. A radiometal, lutetium-177 (Lu-177), was incorporated into the butylamino-NorBIRT through 1,4,7,10-tetraazacyclododecane-N,N',N",N'''- tetraacetic acid (DOTA) as a chelator. RESULTS Equilibrium-binding experiments demonstrated that fluorescein- labeled butylamino-NorBIRT specifically binds human and murine LFA-1 with affinity constants of 135 and 186 nM, respectively. Dissociation kinetic experiments demonstrated an off-rate of 0.168/second(1) on murine cells, consistent with the observed affinity constant. Lutetium-177 was used for labeling, with > or =99.99% radiochemical purity and incorporation yield. This radiolabeled derivative exhibited high stability in fetal bovine serum (FBS) at 37 degrees C over 72 hours. (177)Lu-DOTA-butylamino-NorBIRT showed a binding affinity of 235 nM to human LFA-1 for equilibrium binding and competitive binding experiments. CONCLUSIONS The radiolabeled DOTA-butylamino-NorBIRT may have potential as a noninvasive imaging or therapeutic agent in both human and mouse models.
Collapse
Affiliation(s)
- Rahul B Poria
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | | | | | | | | | |
Collapse
|
12
|
Sun H, Xu XL, Xu LC, Song L, Hong X, Chen JF, Cui LB, Wang XR. Antiandrogenic activity of pyrethroid pesticides and their metabolite in reporter gene assay. Chemosphere 2007; 66:474-9. [PMID: 16857237 DOI: 10.1016/j.chemosphere.2006.05.059] [Citation(s) in RCA: 95] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2006] [Revised: 05/29/2006] [Accepted: 05/31/2006] [Indexed: 05/10/2023]
Abstract
Many pesticides possess hormonal activity and have thus been classified as endocrine disruptors. Pyrethroids are commonly used pesticides worldwide, but little has been done to characterize their antiandrogenic activity potential. We tested three frequently encountered pyrethroids (fenvalerate, cypermethrin, permethrin) and their metabolite 3-phenoxybenzoic acid (3-PBA) for antiandrogenic and androgenic activity using a human androgen receptor (AR) mediated luciferase reporter gene assay in CV-1 African green monkey kidney cell. The assay displayed appropriate response to the known AR agonist 5alpha-dihydrotestosterone and AR antagonist nilutamide and flutamide. At 0.1mM, all the three tested pyrethroids significantly suppressed the luciferase expression. Further, their metabolite 3-PBA also showed antagonist activity. None of the test chemicals showed androgenic activity. Through the antiandrogenic pathways, exposure to certain pyrethroids may contribute to the damage of reproductive system. In conclusion, pyrethroid pesticides can act as antiandrogen in vitro, and metabolizing to 3-PBA cannot eliminate the antagonist activity. This result provides useful information for risk assessment of pyrethroid pesticides.
Collapse
Affiliation(s)
- Hong Sun
- Department of Public Health, Key Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing Medical University, Nanjing 210029, Jiangsu, PR China
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Potapenko DI, Foster MA, Lurie DJ, Kirilyuk IA, Hutchison JMS, Grigor'ev IA, Bagryanskaya EG, Khramtsov VV. Real-time monitoring of drug-induced changes in the stomach acidity of living rats using improved pH-sensitive nitroxides and low-field EPR techniques. J Magn Reson 2006; 182:1-11. [PMID: 16798033 DOI: 10.1016/j.jmr.2006.06.002] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/06/2006] [Revised: 04/18/2006] [Accepted: 06/04/2006] [Indexed: 05/10/2023]
Abstract
New improved pH-sensitive nitroxides were applied for in vivo studies. An increased stability of the probes towards reduction was achieved by the introduction of the bulky ethyl groups in the vicinity of the paramagnetic NO fragment. In addition, the range of pH sensitivity of the approach was extended by the synthesis of probes with two ionizable groups, and, therefore, with two pKa values. Stability towards reduction and spectral characteristics of the three new probes were determined in vitro using 290 MHz radiofrequency (RF)- and X-band electron paramagnetic resonance (EPR), longitudinally detected EPR (LODEPR), and field-cycled dynamic nuclear polarization (FC-DNP) techniques. The newly synthesized probe, 4-[bis(2-hydroxyethyl)amino]-2-pyridine-4-yl-2,5,5-triethyl-2,5-dihydro-1H-imidazol-oxyl, was found to be the most appropriate for the application in the stomach due to both higher stability and convenient pH sensitivity range from pH 1.8 to 6. LODEPR, FC-DNP and proton-electron double resonance imaging (PEDRI) techniques were used to detect the nitroxide localization and acidity in the rat stomach. Improved probe characteristics allowed us to follow in vivo the drug-induced perturbation in the stomach acidity and its normalization afterwards during 1 h or longer period of time. The results show the applicability of the techniques for monitoring drug pharmacology and disease in the living animals.
Collapse
|
14
|
Roscić M, Horvat S. Transformations of bioactive peptides in the presence of sugars—Characterization and stability studies of the adducts generated via the Maillard reaction. Bioorg Med Chem 2006; 14:4933-43. [PMID: 16563774 DOI: 10.1016/j.bmc.2006.03.006] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2005] [Revised: 03/02/2006] [Accepted: 03/08/2006] [Indexed: 11/18/2022]
Abstract
Glycation of biomolecules, such as proteins, peptide hormones, nucleic acids, and lipids, may be a major contributor to the pathological manifestations of aging and diabetes mellitus. These nonenzymatic reactions, also termed the Maillard reaction, alter the biological and chemical properties of biomolecules. In order to investigate the effect of various reducing sugars on the products formed from small bioactive peptides (Tyr-Gly-Gly-Phe-Leu, Tyr-Gly-Gly-Phe-Leu-NH2, Tyr-Gly-Gly-Phe-Leu-OMe, Tyr-Gly-Gly-Phe, and Tyr-Gly-Gly), model systems were prepared with glucose, mannose or galactose. Peptide-sugar mixtures were incubated at 37 or 50 degrees C in phosphate-buffered saline, pH 7.4, or in methanol. The extent of glycation was determined periodically by RP HPLC. All sugar-peptide mixtures generated two different types of glycation products: N-(1-deoxy-ketos-1-yl)-peptide (Amadori compound) and the imidazolidinone compound substituted by sugar pentitol and peptide residue. The amount and distribution of peptide glycation products depended on the structure of the reactants, and increased in both concentration- and time-dependent manner in relation to exposure to sugar. Additionally, the rate of hydrolysis of glucose-derived imidazolidinone compounds, obtained either from leucine-enkephalin (1) or its shorter N-terminal fragments 2 and 3, was determined by incubation at 37 degrees C in human serum. These results revealed that imidazolidinones obtained from glucose and small peptides are almost completely protected from the action of enzymes in serum, the predominant route of degradation being spontaneous hydrolysis to initial sugar and peptide compound.
Collapse
Affiliation(s)
- Maja Roscić
- Division of Organic Chemistry and Biochemistry, Ruder Bosković Institute, PO Box 180, 10002 Zagreb, Croatia
| | | |
Collapse
|
15
|
Haltli B, Tan Y, Magarvey NA, Wagenaar M, Yin X, Greenstein M, Hucul JA, Zabriskie TM. Investigating beta-hydroxyenduracididine formation in the biosynthesis of the mannopeptimycins. ACTA ACUST UNITED AC 2006; 12:1163-8. [PMID: 16298295 DOI: 10.1016/j.chembiol.2005.09.013] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2005] [Revised: 09/01/2005] [Accepted: 09/21/2005] [Indexed: 11/23/2022]
Abstract
The mannopeptimycins (MPPs) are potent glycopeptide antibiotics that contain both D and L forms of the unique, arginine-derived amino acid beta-hydroxyenduracididine (betahEnd). The product of the mppO gene in the MPP biosynthetic cluster resembles several non-heme iron, alpha-ketoglutarate-dependent oxygenases, such as VioC and clavaminate synthase. The role of MppO in betahEnd biosynthesis was confirmed through inactivation of mppO, which yielded a strain that produced dideoxy-MPPs, indicating that mppO is essential for generating the beta-hydroxy functionality for both betahEnd residues. Characterization in vitro of recombinant His6-MppO expressed in E. coli revealed that MppO selectively hydroxylates the beta carbon of free L-enduracididine.
Collapse
Affiliation(s)
- Brad Haltli
- Natural Products Discovery, Wyeth Research, Pearl River, New York 10965, USA.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Ask K, Décologne N, Ginies C, Låg M, Boucher JL, Holme JA, Pelczar H, Camus P. Metabolism of nilutamide in rat lung. Biochem Pharmacol 2006; 71:377-85. [PMID: 16313887 DOI: 10.1016/j.bcp.2005.10.034] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2005] [Revised: 10/14/2005] [Accepted: 10/20/2005] [Indexed: 11/29/2022]
Abstract
Nilutamide is a non-steroidal anti-androgen drug proposed in the treatment of metastatic prostatic carcinoma. Its therapeutic effects are overshadowed by the occurrence of adverse reactions, mediated by mechanisms that remain elusive. To elucidate possible mechanisms for nilutamide toxicity, we investigated the metabolism of nilutamide in rat lung homogenates, in subcellular fractions and in freshly isolated cells. In whole lung homogenates, the nitro group of nilutamide was reduced to the amine and hydroxylamine moieties. These conversions occurred exclusively in the absence of dioxygen, were increased by the addition of FMN, FAD, or NADPH. Reductive metabolism of nilutamide to the amine and hydroxylamine was further evidenced in subcellular fractions obtained by differential ultracentrifugation. It was found to take place mainly in the cytosol of rat lung and to be stimulated, strongly, upon co-addition of NADPH and FMN. Addition of inhibitors of enzymes involved in the reductive metabolism of nitroaromatic compounds indicated that reduction of nilutamide involved, mainly, soluble flavoproteins. Incubations with freshly isolated lung cells revealed that macrophages were the main players in nitroreduction of nilutamide whereas the epithelial type II cells and the non-ciliated Clara cells were less efficient in catalyzing this reaction. Our results show that nilutamide is extensively reduced by lung tissues in the absence of oxygen, especially by enzymes found in alveolar macrophages. In accordance with recent findings, subcellular localization, oxygen sensitivity, cofactor requirements and inhibitor studies lead us to suggest the involvement of a soluble nitric oxide synthase in lung cytosolic nitroreduction.
Collapse
Affiliation(s)
- Kjetil Ask
- Laboratory of Pulmonary Pharmacology and Toxicology, UMR INRA/Université de Bourgogne 1234, Faculté de Médecine et de Pharmacie, Dijon, France.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Larson RS, Davis T, Bologa C, Semenuk G, Vijayan S, Li Y, Oprea T, Chigaev A, Buranda T, Wagner CR, Sklar LA. Dissociation of I domain and global conformational changes in LFA-1: refinement of small molecule-I domain structure-activity relationships. Biochemistry 2005; 44:4322-31. [PMID: 15766261 DOI: 10.1021/bi048187k] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
LFA-1 (alphalbeta2) is constitutively expressed on leukocytes, but its activity is rapidly regulated. This rapid activation has been proposed to be associated with conformation changes in the inserted ("I") domain within the headpiece of LFA-1 as well as conversion of the molecules from bent to extended forms. To study these molecular changes as they relate to affinity regulation of LFA-1, we developed and synthesized a fluorescent derivative of BIRT-377 [Kelly et al. (2001) J. Immunol.] to examine changes in LFA-1 affinity in a flow cytometer with live cells. BIRT-377 binds to the ligand-binding or "I" domain of LFA-1. Structure-activity relationships studies indicated that an aminoalkyl group could be added to the central hydantoin group without significantly affecting binding. Using this modified derivative [1-(N-fluoresceinylthioureidobutyl)-[5R]-(4-bromobenzyl)-3-(3,5-dichlorophenyl)-5-methyl-imidazolidine-2,4-dione (FBABIRT)], we analyzed the affinity of FBABIRT binding to LFA-1 on live cells. The binding affinity increases, and the dissociation rate decreases with divalent cation (Mn(2+)) stimulation. We then used FBABIRT with fluorescent resonance energy transfer (FRET) to show that LFA-1 changes its height relative to the cell surface when cells were treated with dithiothreitol (DTT) but not Mn(2+). Competition assays among FBABIRT and BIRT derivatives defined structure-affinity relationships that refine the current model of BIRT-377 binding to the I domain. Our data supports the model in which BIRT-377 binds to the I domain and stabilizes the bent structure of LFA-1, while divalent cation activation results in a small conformational change in the I domain without significant extension of LFA-1. DTT, in contrast, induces a conversion to the extended form of LFA-1 in the presence of BIRT-377 on live cells. The structure-activity studies suggest that BIRT-377 is a fully optimized inhibitor.
Collapse
Affiliation(s)
- Richard S Larson
- Department of Pathology, University of New Mexico, and Cancer Research and Treatment Center, Albuquerque, New Mexico 87131-5301, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Abstract
AIM To assess the influence of ketoconazole on azimilide pharmacokinetics. METHODS A two-period randomized crossover study was conducted in healthy male and female subjects (19-45 years). Placebo or 200 mg ketoconazole were administered orally every 24 h for 29 days. On day 8, a single oral dose of 125 mg azimilide dihydrochloride was coadministered following an overnight fast. Blood samples were obtained prior to and for 22 days following azimilide dihydrochloride administration. The plasma protein binding of azimilide was also assessed at 6 h after dosing. RESULTS Following ketoconazole administration, a 16% increase in azimilide AUC (90% confidence interval (CI) 112%, 120%), a 12% increase in C(max) (95% CI 107%, 116%), a 13% increase in t(1/2,z) (95% CI 107%, 120%) and a 14% decrease in CL(o) (95% CI 82%, 90%) were observed. CONCLUSIONS The changes in azimilide pharmacokinetics following ketoconazole treatment are not clinically important since the 90% CI for the AUC fell within the prespecified range of 80-125%. Thus, no clinically important drug interactions are expected when azimilide dihydrochloride is coadministered with CYP3A4 inhibitors.
Collapse
Affiliation(s)
- Mohamed El Mouelhi
- Procter & Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Road, Mason, OH 45040-9462, USA
| | | | | | | | | |
Collapse
|
19
|
Sztanke K, Fidecka S, Kedzierska E, Karczmarzyk Z, Pihlaja K, Matosiuk D. Antinociceptive activity of new imidazolidine carbonyl derivatives. Eur J Med Chem 2005; 40:127-34. [PMID: 15694647 DOI: 10.1016/j.ejmech.2004.09.020] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2004] [Revised: 09/01/2004] [Accepted: 09/06/2004] [Indexed: 11/25/2022]
Abstract
Synthesis and pharmacological activity of 8-aryl-3,4-dioxo-2H,8H-6,7-dihydroimidazo[2,1-c] [1,2,4]triazines (A) are presented. The title compounds were obtained from 1-aryl-2-hydrazinoimidazolines (1) by cyclization reaction with ethyl oxalate (2). They were tested for pharmacological activity in behavioral animal tests (A1, A3, A5, A6, A8, A9). With relatively low acute toxicity (LD50 in range from 1100 to over 2000 mg kg(-1), intraperitoneally, i.p.), some of them exhibited significant antinociceptive activity as the result of the 'writhing' test indicated. Especially strong antinociception for compound A8 and significant for A6 was observed in doses of 12.5-200 mg (0.00625-0.1 LD50) and 37.5-150 mg (0.025-0.1 LD50), respectively. Reversion of the antinociception for A1 and A8 produced in the 'writhing' test by 5 mg kg(-1) dose of naloxon can suggest an opioid-like mechanism of their analgesic activity. Additionally, compound A9 reduced number of the "head twitch" episodes after 5-hydroxytryptophan (5-HTP) administration with no antinociceptive effect at all and compound A3 showed significant protection in the pentylentetrazol-induced seizure model. Differences observed in the activity spectrum between A8 and A9 derivatives can be explained on the base of difference in the amido-imido tautomeric equilibrium observed between these two compounds.
Collapse
Affiliation(s)
- Krzysztof Sztanke
- Department of Synthesis and Technology of Drugs, Medical University, Staszica 6, 20-081 Lublin, Poland
| | | | | | | | | | | |
Collapse
|
20
|
Ask K, Décologne N, Asare N, Holme JA, Artur Y, Pelczar H, Camus P. Distribution of nitroreductive activity toward nilutamide in rat. Toxicol Appl Pharmacol 2004; 201:1-9. [PMID: 15519603 DOI: 10.1016/j.taap.2004.04.006] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2004] [Accepted: 04/12/2004] [Indexed: 11/23/2022]
Abstract
Nilutamide is a pneumotoxic and hepatotoxic nitroaromatic (R-NO2) antiandrogen used in the treatment of prostate carcinoma in man. Previously, we established that in the rat lung, the drug is metabolized into the corresponding hydroxylamine (R-NHOH) and amine (R-NH2) derivatives. These results evidenced a cytosolic oxygen-sensitive (type II) nitroreductase activity in lung. In the present studies, we extended the characterization of nilutamide metabolism in liver, brain, kidney, heart, blood, intestine (small, cecum, and large, and their respective luminal contents) of male Sprague-Dawley rats. Subcellular fractions for all tissues (except blood) examined (postmitochondrial, cytosolic, and microsomal) were prepared by differential ultracentrifugation. Blood and intestinal contents were sonicated before investigation. Incubations were run in the presence or absence of O2 to assess type I and II nitroreductase activities. Organic extracts were analyzed by HPLC methods and results were expressed as pmoles of R-NH2 formed per milligram protein per minute. Four distinct nitroreductive activities were evidenced. Cytosolic and microsomal type II nitroreductase activities were detected in all tissue samples studied. Type I NR activity was not observed in any of the cytosols, but was detected in the small intestine, lung, kidney, and liver microsomes. Nilutamide was also reduced in the intestinal lumen, possibly by a bacterial type I nitroreductase. Highest activities were observed in cytosols and were oxygen sensitive. These results evidence and characterize previously unknown nitroreductive activities toward nilutamide in rat tissues that might provide some explanation to the side effects of nilutamide and other nitroaromatic compounds observed in human therapeutics.
Collapse
Affiliation(s)
- Kjetil Ask
- Division of Pulmonary and Intensive Care, and Laboratory of Pulmonary Pharmacology and Toxicology, Facultés de Médecine et de Pharmacie, UMR INRA/Université de Bourgogne 1234, 21000 Dijon, France.
| | | | | | | | | | | | | |
Collapse
|